We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+40.64%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$587M
AUM Growth
+$37.7M
Cap. Flow
-$98.3M
Cap. Flow %
-16.76%
Top 10 Hldgs %
58.11%
Holding
52
New
10
Increased
8
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$15.8M
2
NGNE icon
Neurogene
NGNE
+$14.2M
3
TRML
Tourmaline Bio
TRML
+$11.5M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$8.68M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$7.03M

Top Sells

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$19.4M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$11.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$11.2M
4
REPL icon
Replimune Group
REPL
+$10.9M
5
ACLX
Arcellx
ACLX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
$70.6M 12.03%
3,703,433
+624,800
+20% +$8.68M
CYTK icon
2
Cytokinetics
CYTK
$10.5B
$41.7M 7.11%
500,000
-100,000
-17% -$3.62M
URGN icon
3
UroGen Pharma
URGN
$1.86B
$39.3M 6.7%
2,620,545
– –
PLRX icon
4
Pliant Therapeutics
PLRX
$64.4M
$33M 5.63%
1,823,184
+68,000
+4% +$1.03M
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.45B
$31M 5.28%
648,000
-79,426
-11% -$3.08M
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.06B
$27.6M 4.71%
600,000
+99,999
+20% +$3.53M
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
$27.3M 4.66%
137,469
-44,790
-25% -$5.54M
ALKS icon
8
Alkermes
ALKS
$8.22B
$24.3M 4.14%
875,044
– –
JBIO
9
Jade Biosciences
JBIO
$1.2B
$23.5M 4%
29,648
-1,530
-5% -$780K
PCVX icon
10
Vaxcyte
PCVX
$7.81B
$22.6M 3.85%
360,000
-171,211
-32% -$8.89M
EOLS icon
11
Evolus
EOLS
$385M
$21.1M 3.59%
2,000,000
-186,934
-9% -$1.67M
ANAB icon
12
AnaptysBio
ANAB
$1.58B
$20.9M 3.57%
976,981
+82,648
+9% +$1.43M
IMCR icon
13
Immunocore
IMCR
$1.72B
$20M 3.41%
293,000
+2,083
+0.7% +$108K
NGNE icon
14
Neurogene
NGNE
$656M
$19.3M 3.28%
+994,229
New +$14.2M
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$18.2M 3.1%
1,280,500
+423,500
+49% +$4.81M
TRML
16
DELISTED
Tourmaline Bio
TRML
$17.6M 3%
672,885
+572,885
+573% +$11.5M
ABVX
17
Abivax
ABVX
$10.9B
$16.6M 2.83%
+1,550,000
New +$15.8M
ZURA icon
18
Zura Bio
ZURA
$516M
$15.4M 2.62%
3,295,000
– –
OPTN
19
DELISTED
OptiNose
OPTN
$11.4M 1.94%
589,329
– –
APGE icon
20
Apogee Therapeutics
APGE
$10.1B
$11.2M 1.9%
400,000
– –
ARVN icon
21
Arvinas
ARVN
$518M
$9.63M 1.64%
+234,082
New +$5.47M
KRTX
22
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.57M 1.63%
30,250
-30,250
-50% -$5.88M
VTGN icon
23
VistaGen Therapeutics
VTGN
$9.89M
$9.55M 1.63%
+1,858,735
New +$7.03M
TERN
24
DELISTED
Terns Pharmaceuticals
TERN
$8.5M 1.45%
1,309,975
+664,076
+103% +$3.51M
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.92M 1.35%
110,607
-114,393
-51% -$6.58M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Great Point Partners held 52 positions worth $587M, up 6.9% from $549M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $98.3M in Q4 2023, closing 18 positions and reducing 11 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $19.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Abivax worth $16.6M.

  • Great Point Partners's largest Q4 2023 buy was Abivax: 1,550,000 shares worth $16.6M.
  • Great Point Partners added most to Tourmaline Bio in Q4 2023, an estimated $11.5M increase.
  • Great Point Partners's biggest Q4 2023 reduction was Arcellx, cutting an estimated $10.8M.
  • Great Point Partners fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $19.4M.
  • Great Point Partners's ten largest holdings make up 58% of its $587M portfolio in Q4 2023.
  • Great Point Partners opened 10 new positions and closed 18 in Q4 2023.
  • Great Point Partners's portfolio value rose 6.9% quarter-over-quarter to $587M.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.